CDK 4/6抑制剂对转移性乳腺癌的肾脏不良结果。
Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.
发表日期：2023 Aug 19
作者：
Paul E Hanna, Ian A Strohbehn, Daiana Moreno, Destiny Harden, Rituvanthikaa Seethapathy, Rani Sawtell, Qiyu Wang, Tianqi Ouyang, Nurit Katz-Agranov, James Dinulos, Seth A Wander, Shruti Gupta, Meghan E Sise
来源：
DIABETES & METABOLISM
摘要：
细胞周期依赖性激酶（CDK）4/6抑制剂显著提高了转移性乳腺癌患者的总体生存率和无进展生存率，但其对短期和长期肾功能的影响尚不清楚。我们发现，在接受CDK 4/6抑制剂治疗的患者中，早期轻度估计的肾小球滤过率（eGFR）下降较为普遍；然而，严重的肾损伤较为罕见，长期eGFR下降不常见。© 2023. Springer Nature Limited.
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.© 2023. Springer Nature Limited.